Montgomery, Stuart A.

A new depression scale designed to be sensitive to change

Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major Depression

Cited by 13,962

Social Functioning in Depression: A Review

Hirschfeld, R. M. A., Montgomery, S. A., Keller, M. B., Kasper, S., Schatzberg, A. F., Moller, H.-J., Healy, D., Baldwin, D., Humble, M., Versiani, M., et al. (2000) · The Journal of Clinical Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 586

Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder: Results From a European Multicenter Study

Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 521

Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey

Wittchen, H.-U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000) · International Clinical Psychopharmacology

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMental Health Treatment and Access

Cited by 299

A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?

Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 295

Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder

Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 286

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 196

Humanistic and economic burden of generalized anxiety disorder in North America and Europe

Revicki, D. A., Travers, K., Wyrwich, K. W., Svedsäter, H., Locklear, J., Mattera, M. S., Sheehan, D. V., & Montgomery, S. (2012) · Journal of Affective Disorders

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMental Health Treatment and Access

Cited by 172

A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder

Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 168

Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice

Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 152

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study

Kautzky, A., Dold, M., Bartova, L., Spies, M., Kranz, G. S., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Fabbri, C., et al. (2019) · Acta Psychiatrica Scandinavica

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 148

A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine

Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 143

Discontinuation symptoms in depression and anxiety disorders

Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 140

Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders: results from a European multicenter study

Dold, M., Bartova, L., Souery, D., Mendlewicz, J., Serretti, A., Porcelli, S., Zohar, J., Montgomery, S., & Kasper, S. (2017) · Journal of Psychiatric Research

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 131

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder

Vieta, E., Montgomery, S., Sulaiman, A. H., Cordoba, R., Huberlant, B., Martinez, L., & Schreiner, A. (2012) · European Neuropsychopharmacology

Bipolar Disorder and TreatmentSchizophrenia research and treatment

Cited by 130

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder

Durgam, S., Earley, W., Guo, H., Li, D., Németh, G., Laszlovszky, I., Fava, M., & Montgomery, S. A. (2016) · The Journal of Clinical Psychiatry

Treatment of Major DepressionSchizophrenia research and treatment

Cited by 125

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

Montgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology

Treatment of Major DepressionStatistical Methods in Clinical Trials

Cited by 121

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder

Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major Depression

Cited by 115

A New Prediction Model for Evaluating Treatment-Resistant Depression

Kautzky, A., Baldinger-Melich, P., Kranz, G. S., Vanicek, T., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Serretti, A., Lanzenberger, R., et al. (2017) · The Journal of Clinical Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 94

Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study

Perahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J. (2006) · British Journal of Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 94

Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study

Robert, P., Montgomery, S. A., Darcourt, G., Robert, G., Houillon, P., Bouchard, J. M., Tatossian, A., Planche, R., Bourgeois, M., Richou, H., et al. (1995) · International Clinical Psychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 85

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)

Dold, M., Bartova, L., Fugger, G., Kautzky, A., Souery, D., Mendlewicz, J., Papadimitriou, G. N., Dikeos, D., Ferentinos, P., Porcelli, S., et al. (2018) · International Journal of Neuropsychopharmacology

Suicide and Self-Harm StudiesTreatment of Major Depression

Cited by 82

Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study

Montgomery, S. A., Mansuy, L., Ruth, A., Bose, A., Li, H., & Li, D. (2013) · The Journal of Clinical Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 78

Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder

Kocabas, N. A., Antonijevic, I., Faghel, C., Forray, C., Kasper, S., Lecrubier, Y., Linotte, S., Massat, I., Mendlewicz, J., Noro, M., et al. (2011) · International Clinical Psychopharmacology

Genetic Associations and EpidemiologyTreatment of Major Depression

Cited by 74